Biochemical Engineering
CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute
17th March 2020
The German biotech CureVac — which is developing an mRNA vaccine against coronavirus — has been granted up to €80M by the European Commission, shortly after a dispute erupted over an alleged acquisition offer from the US. The money was awarded to help CureVac quickly scale up the production of its candidate Covid-19 vaccine. It came one day after allegations from the German newspaper Welt am Sonntag claiming that US President Donald Trump intended to acquire the vaccine for exclusive use in the US. Source: Labiotech 17/3/2020
Back to group news